Movement Alert｜METiS Pharmaceuticals-P Declines 5.21% in Regular Trading, Post-IPO Pullback Continues as New Stock Enthusiasm Fades

Market Focus05-28

On May 28, METiS Pharmaceuticals-P (07666.HK) declined 5.21% in regular trading, trading at HK$16.32 per share, with trading volume of HK$17.99 million.

On the news front, the stock has been in sustained retreat since its listing debut on May 13, when it surged 173% from its IPO price of HK$10.50. As the world's first AI-driven drug delivery company to list on the Hong Kong Stock Exchange, METiS remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure post-listing.

Although the company recently launched its AiProtein platform and announced a strategic alliance with Deerfield to advance AI-driven protein therapeutics and in-vivo immunotherapy, post-IPO market enthusiasm has continued to cool rapidly, sustaining downward pressure on the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138550889?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 11:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138550889","market":"hk","top_or_hot":-1,"title":"Movement Alert｜METiS Pharmaceuticals-P Declines 5.21% in Regular Trading, Post-IPO Pullback Continues as New Stock Enthusiasm Fades","media":"Market Focus","content":"<p><p>On May 28, METiS Pharmaceuticals-P (07666.HK) declined 5.21% in regular trading, trading at HK$16.32 per share, with trading volume of HK$17.99 million.</p><p>On the news front, the stock has been in sustained retreat since its listing debut on May 13, when it surged 173% from its IPO price of HK$10.50. As the world's first AI-driven drug delivery company to list on the Hong Kong Stock Exchange, METiS remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure post-listing.</p><p>Although the company recently launched its AiProtein platform and announced a strategic alliance with Deerfield to advance AI-driven protein therapeutics and in-vivo immunotherapy, post-IPO market enthusiasm has continued to cool rapidly, sustaining downward pressure on the share price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜METiS Pharmaceuticals-P Declines 5.21% in Regular Trading, Post-IPO Pullback Continues as New Stock Enthusiasm Fades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜METiS Pharmaceuticals-P Declines 5.21% in Regular Trading, Post-IPO Pullback Continues as New Stock Enthusiasm Fades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 11:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, METiS Pharmaceuticals-P (07666.HK) declined 5.21% in regular trading, trading at HK$16.32 per share, with trading volume of HK$17.99 million.</p><p>On the news front, the stock has been in sustained retreat since its listing debut on May 13, when it surged 173% from its IPO price of HK$10.50. As the world's first AI-driven drug delivery company to list on the Hong Kong Stock Exchange, METiS remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure post-listing.</p><p>Although the company recently launched its AiProtein platform and announced a strategic alliance with Deerfield to advance AI-driven protein therapeutics and in-vivo immunotherapy, post-IPO market enthusiasm has continued to cool rapidly, sustaining downward pressure on the share price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07666","symbol_name":"剂泰科技-P","start_time":0,"source_url":"","article_id":"1138550889","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138550889","pubTimestamp":1779939827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, METiS Pharmaceuticals-P (07666.HK) declined 5.21% in regular trading, trading at HK$16.32 per share, with trading volume of HK$17.99 million.On the news front, the stock has been in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07666":"剂泰科技-P"},"translate_title":"动向提示|METiS Pharmaceuticals-P常规交易下跌5.21%新股热情消退IPO后回调持续","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07666":1},"content_text":"On May 28, METiS Pharmaceuticals-P (07666.HK) declined 5.21% in regular trading, trading at HK$16.32 per share, with trading volume of HK$17.99 million.On the news front, the stock has been in sustained retreat since its listing debut on May 13, when it surged 173% from its IPO price of HK$10.50. As the world's first AI-driven drug delivery company to list on the Hong Kong Stock Exchange, METiS remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure post-listing.Although the company recently launched its AiProtein platform and announced a strategic alliance with Deerfield to advance AI-driven protein therapeutics and in-vivo immunotherapy, post-IPO market enthusiasm has continued to cool rapidly, sustaining downward pressure on the share price.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138550889","isCrawlerRequest":true}